Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vemurafenib + aldesleukin
- Development stage
- Phase 2
- Lead developer
- Daiichi Sankyo
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral (vemurafenib), Intravenous (aldesleukin)
01
Overview
Vemurafenib + aldesleukin is a combination of a targeted small molecule kinase inhibitor (vemurafenib) and a recombinant cytokine (aldesleukin, also known as interleukin-2). Vemurafenib selectively inhibits the mutant BRAF kinase (especially BRAF V600E), blocking the MAPK pathway signaling required for the growth of certain melanomas. Aldesleukin activates CD8 T cells and other immune effector cells, aiming to stimulate anti-tumor immunity. This combination has been investigated for its ability to leverage tumor microenvironment changes induced by BRAF inhibition and increase immune infiltration through cytokine therapy. The main indication under investigation is unresectable or metastatic melanoma harboring the BRAF V600E mutation[1][5][7].
- Brand names
- Zelboraf + Proleukin
- Other names
- vemurafenib + interleukin-2vemurafenib + IL-2vemurafenib + HD-IL-2
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on vemurafenib + aldesleukin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vemurafenib + aldesleukin.